Collaboration expanded to explore synthetically feasible chemical space
Enamine REAL database of synthetic compounds accessible via UCSF’s online ZINC platform.
Enamine, a chemical research organization and producer of novel building blocks and screening libraries, has expanded its collaboration on ZINC, a comprehensive online database of purchasable compounds curated by the Irwin and Shoichet laboratories in the Department of Pharmaceutical Chemistry at the University of California, San Francisco (UCSF). Via ZINC, Enamine will provide researchers at UCSF and the global drug-discovery community with access to the company’s REAL database, a unique database of more than 300 million novel synthetically feasible chemical structures as an efficient source of potential new compounds for a breadth of drug discovery projects.
The REAL database is the most significant contribution to currently purchasable chemical space, accounting for over 90% of all structures in ZINC. The compounds are conveniently selected in ZINC and then synthesized by Enamine in a single step from its building block stock, ensuring quick delivery and a high success rate.
Michael Bossert, Head of Strategic Alliances at Enamine said: “The number of compounds that Enamine can quickly access with its stock of 150,000 building blocks is astonishing. ZINC is a powerful platform that can efficiently support our endeavors to further expand our chemical space coverage to the global drug discovery community. We are pleased to see the researchers at UCSF benefitting from the diversity and novelty of our structures in the REAL compound arrays.”
John Irwin, Adjunct Professor at the UCSF School of Pharmacy and curator of ZINC agreed: “As we strive to bridge the gap between chemoinformatics and biology, the importance of working within a purchasable chemical space cannot be underestimated. We are pleased to continue our collaboration with Enamine in exploring ways to provide novel chemical compounds, designed and synthesized specifically for each research project, to the global biomedical community.”
Most compounds from the REAL database have already been successfully uploaded to ZINC. Over the last year, 92% of the more than 250 compounds ordered from Enamine have been delivered successfully to UCSF.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.